NAMS icon

NewAmsterdam Pharma
NAMS

Upgrade to unlock
Buy
Hold
Sell

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
Avg. target
$48
16% upside
High target

4 analyst ratings

positive
0  neutral
0%
negative
Analyst & Firm Rating Price Target Upside
Downside 		Date
RBC Capital
RBC Capital
Leonid Timashev
100% 1-yr NAMS win rate
6 Nov ‘25 24 days ago
Needham
Needham
Serge Belanger
83% 1-yr NAMS win rate
5 Nov ‘25 25 days ago
HC Wainwright & Co
HC Wainwright & Co
Joseph Pantginis
100% 1-yr NAMS win rate
20 Oct ‘25 1 month ago
Citigroup
Citigroup
Geoff Meacham
100% 1-yr NAMS win rate
17 Oct ‘25 1 month ago